# US 7,608,580 B2 · Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,580 B2 - Document ID: US7608580B2 - Status: Granted - Kind: B2 - Application number: 11/624,463 - Filed: 2007-01-18 - Published: 2007-06-14 - Granted: 2009-10-27 - Earliest claimed: 1999-10-15 - Assignees: Genetics Institute, Inc.; Fidia Advanced Biopolymers S.r.l. - Inventors: Hyun Kim; Rebecca Li; Alessandra Pavesio; Lanfranco Callegaro; Howard Seeherman; John Wozney - Web page: https://patentgrep.com/patent/US7608580B2 ## CPC - A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor} - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61L 27/20: Polysaccharides - A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24} - A61L 27/46: with phosphorus-containing inorganic fillers - A61P 19/00: Drugs for skeletal disorders - A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease - A61L 2300/414: Growth factors - A61L 2400/06: Flowable or injectable implant compositions - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phosphate are also disclosed. Methods for formulating porous injectable gels and pastes from hyaluronic acid are also disclosed. ## Claims ### Claim 1 A method for promoting bone, cartilage, or tendon formation in a patient comprising injecting an osteogenic composition through the skin of the patient to a site in need of bone formation, wherein the composition comprises (a) an osteogenic protein, (b) an injectable hyaluronic acid ester, and (c) a pore former selected from a liquid pore former or sodium bicarbonate. ### Claim 2 (depends on 1) The method of claim 1, wherein the composition is administered by intraosseous injection. ### Claim 3 (depends on 1) The method of claim 1, wherein the method of promoting bone formation comprises distraction osteogenesis. ### Claim 4 (depends on 1) The method of claim 1, wherein the method of promoting bone formation comprises repair of a bone defect. ### Claim 5 (depends on 4) The method of claim 4, wherein the repair of a bone defect comprises closed fracture repair. ### Claim 6 (depends on 4) The method of claim 4, wherein the bone defect is a bone fracture. ### Claim 7 (depends on 4) The method of claim 4, wherein the bone defect is osteoporosis. ### Claim 8 (depends on 4) The method of claim 4, wherein the bone defect is a non-union bone fracture. ### Claim 9 (depends on 1) The method of claim 1, wherein the osteogenic protein is selected from the group consisting of Bone Morphogenic Protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12. ### Claim 10 (depends on 1) The method of claim 1, wherein the hyaluronic acid ester is selected from the group consisting of 100% esterified benzyl ester hyaluronic acid ester, 80% esterified benzyl ester hyaluronic acid ester, and 65% esterified benzyl ester hyaluronic acid ester. ### Claim 11 (depends on 1) The method of claim 1, wherein the composition further comprises tricalcium phosphate (TCP). ### Claim 12 A method for promoting the attachment of ligament to bone in a patient comprising injecting an osteogenic composition through the skin of the patient to a site in need of attachment, wherein the composition comprises (a) an osteogenic protein, (b) an injectable hyaluronic acid ester, and (c) a pore former selected from a liquid pore former or sodium bicarbonate. ### Claim 13 (depends on 12) The method of claim 12, wherein the osteogenic protein is selected from the group consisting of Bone Morphogenic Protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12. ### Claim 14 (depends on 12) The method of claim 12, wherein the hyaluronic acid ester is selected from the group consisting of 100% esterified benzyl ester hyaluronic acid ester, 80% esterified benzyl ester hyaluronic acid ester, and 65% esterified benzyl ester hyaluronic acid ester. ### Claim 15 (depends on 12) The method of claim 12, wherein the composition further comprises tricalcium phosphate (TCP).